H.C. Wainwright lowered the firm’s price target on Humacyte (HUMA) to $3 from $4 and keeps a Buy rating on the shares. The firm says the company’s July sales growth suggests potential momentum.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUMA:
- Humacyte Reports Q2 2025 Earnings and Market Expansion
- Buy Rating Reaffirmed for Humacyte Amid Promising Symvess Launch and Strategic Collaborations
- Humacyte reports Q2 EPS (24c), consensus (18c)
- Is HUMA a Buy, Before Earnings?
- Humacyte’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Josh Jennings